PetVivo Holdings, Inc. Announces Application for Dual Listing on Upstream
MINNEAPOLIS, MN, Dec. 28, 2022 (GLOBE NEWSWIRE) -- PetVivo Holdings, Inc. (NASDAQ: PETV, PETVW) (the "Company" or “PetVivo”) an emerging...
Month: December 2022
CVRx to Present at the 41st Annual J.P. Morgan Healthcare Conference
MINNEAPOLIS, Dec. 28, 2022 (GLOBE NEWSWIRE) -- CVRx, Inc. (“CVRx”), a commercial-stage medical device company focused on developing, manufacturing and...
Aridis Pharmaceuticals to Discuss Topline Data from Phase 3 Study of AR-301 During Corporate Update Call on January 25
Los Gatos, Calif., Dec. 28, 2022 (GLOBE NEWSWIRE) -- Aridis Pharmaceuticals, Inc. (NASDAQ: ARDS), a biopharmaceutical company focused on the...
Nexcella, Inc announces poster presentation at the European Society for Blood and Marrow Transplantation and European Hematology Association 5th Annual European CAR T-cell Meeting
Updated clinical data for NXC-201, a next-generation CAR-T for multiple myeloma and AL amyloidosis, will be presented in Rotterdam, Netherlands...
Opus Genetics Announces Acquisition of the Rights to Two Gene Therapy Product Candidates for Inherited Retinal Diseases
Opus to advance preclinical development programs for BEST1- and RHO-related retinal diseases Deal expands Opus’ addressable patient population for its...
Nexcella, Inc., a subsidiary of Immix Biopharma, announces poster presentation at the European Society for Blood and Marrow Transplantation and European Hematology Association 5th Annual European CAR T-cell Meeting
Updated clinical data for NXC-201, a next-generation CAR-T for multiple myeloma and AL amyloidosis, will be presented in Rotterdam, Netherlands...
PDS Biotech Reports Median Overall Survival (OS) of 21 Months in Advanced, Refractory Cancer Patients Having Few Remaining Treatment Options and with Reported Historical Survival of 3-4 months
Median OS of 21 months in 29 checkpoint inhibitor (CPI) refractory HPV16-positive cancer patients in National Cancer Institute-led Phase 2...
Acasti Announces Preliminary Topline Results Met All Outcome Measures in the Pharmacokinetic Bridging Study for GTX-102, the Company’s Drug Candidate for the Treatment of Ataxia Telangiectasia
LAVAL, Québec, Dec. 28, 2022 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (“Acasti” or the “Company”) (Nasdaq: ACST and TSX-V: ACST),...
Amedisys to Present at the 41st Annual J.P. Morgan Healthcare Conference
BATON ROUGE, La., Dec. 28, 2022 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), a leading provider of home health, hospice,...
FDA Approves Polarean’s XENOVIEW™ (xenon Xe 129 hyperpolarized) for use with MRI for the Evaluation of Lung Ventilation
XENOVIEW represents the first and only hyperpolarized MRI contrast agent ● FDA approved indication includes both adolescents and adults representing...
Minerva Neurosciences Announces Update on its New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia
BURLINGTON, Mass., Dec. 28, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the...
HTG Molecular Diagnostics Provides Highlights of its Second Event in Drug Discovery KOL Webcast Series
TUCSON, Ariz., Dec. 28, 2022 (GLOBE NEWSWIRE) -- HTG Molecular Diagnostics, Inc. (Nasdaq: HTGM) (HTG), a life science company advancing...
Oncotelic Issues Year End Message to Shareholders
– JV continues to advance to its IPO- OT-101 immunotherapy expanding with at least 10 planned IIS clinical trials for...
Aptose Biosciences to Present at Biotech Showcase™ 2023 Conference
SAN DIEGO and TORONTO, Dec. 28, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision...
Crystal Research Update Highlights 100% Responders Rate in Mild to Moderate COVID-19 Trial
Trial meets endpoints in safety and efficacyIND Letter from the CDSCO to optimize dosageEstablishment of an Indian Subsidiary to commercialize...
BioNTech to Present at the 41st Annual J.P. Morgan Healthcare Conference
Mainz, Germany, December 28, 2022 (GLOBE NEWSWIRE) – BioNTech SE (Nasdaq: BNTX, “BioNTech” or “the Company”) announced today that CEO...
CENTOGENE Announces Its Attendance at the 41st Annual J.P. Morgan Healthcare Meeting and Fierce JPM Week in San Francisco
CAMBRIDGE, Mass. and ROSTOCK, Germany and BERLIN, Dec. 28, 2022 (GLOBE NEWSWIRE) -- Centogene N.V. (Nasdaq: CNTG), the essential life...
40,443 Orion Corporation A shares converted into B shares
ORION CORPORATION STOCK EXCHANGE RELEASE - OTHER INFORMATION DISCLOSED ACCORDING TO THE RULES OF THE EXCHANGE28 DECEMBER 2022 at 9.30...
Basilea announces repayment of 2022 convertible bonds
Basel/Allschwil, Switzerland, December 28, 2022 Basilea Pharmaceutica Ltd (SIX: BSLN), a commercial-stage biopharmaceutical company committed to meeting the needs of...
Pixium Vision welcomes judgment by Paris Commercial Court against Second Sight Medical Products
Pixium Vision welcomes judgment by Paris Commercial Court against Second Sight Medical Products Court finds Second Sight Medical Products breached 2021...